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ABSTRACT OF THE THESIS 
 
Investigating Variants of Uncertain Significance:  
Reclassification Triggers and Drivers in Breast Cancer Predisposition Genes 
 
By 
Kirsten Anne Kelly  
Master of Science in Genetic Counseling  
University of California, Irvine, 2019 
Professor Emerita Moyra Smith, MD, PhD, Chair 
 
 
 
       This study investigated the factors that trigger and drive reclassification of DNA 
variants of uncertain significance (VUS) in genes associated with high and moderate breast 
cancer risk (HBRGs and MBRGs). We examined 617 VUS reclassifications in 15 genes 
associated with hereditary breast cancer predisposition performed by a single commercial 
laboratory from January 2014 to January 2018. Almost 81% of the VUS reclassifications 
were downgrades, i.e. a VUS reclassified to likely benign (VLB) or benign. However, for 
VUSs that were reclassified in HBRGs over the study period it was determined that every 
year the odds of upgrade, i.e. a VUS reclassified to likely pathogenic (VLP) or pathogenic, 
increased by 68%. These results are significant considering VUS reclassification to 
pathogenic or VLP can lead to significant medical management changes for patients. 
Additionally, reclassified variants in HBRGs were more likely to use several lines of 
evidence (de novo occurrences, computational data, and protein functional assays) more 
frequently than reclassified variants in MBRGs. There were significant differences seen in 
evidence used depending on the reclassification direction, i.e. upgrade or downgrade. 
Availability of new research or data triggered reclassification of VUSs more frequently in 
x 
 
HBRGs, but periodic variant review triggered reclassification more frequently in MBRGs. 
On average variants in HBRGs were reclassified five months sooner than variants in 
MBRGS. The results of this study support previously published data regarding frequency 
and direction of VUS reclassification and shed new light on the triggers of and evidence 
used for variant reclassification in HBRGs and MBRGs.   
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I. INTRODUCTION 
1.1 Background and Significance of the Research  
 
 
1.1.1 Hereditary cancer susceptibility multigene panel testing                   
  
 The funding of the Human Genome Project (HGP) was the catalyst of the genetics 
resurgence in the 20th century. The HGP was an international, collaborative research 
program whose goal was the complete mapping and understanding of the human genome. 
The 15-year-long project formally launched in April of 1990 and was declared complete in 
April of 2003 and cost a total of $3 billion. The complete mapping of the human genome 
allowed us to better understand the gene-disease relationship by identifying about 20,500 
human genes (National Human Genome Research Institute 2016). Since the completion of 
the project numerous applications of the research have been discovered including but not 
limited to: identification of pathogenic variants linked to human disease, advancement in 
forensic applied sciences, animal husbandry, anthropology, and evolution. One of the most 
notable applications of the project was the commercial development of genomics research 
and products, which is now a multibillion-dollar industry.  
 
Amidst the launch of the HGP a group of researchers at UC Berkeley discovered 
evidence for the existence of a gene involved in breast cancer susceptibility. By comparing 
genetic data from multiple families in which several individuals had a history of breast 
cancer the researchers mapped the gene to a region on the long arm of human 
chromosome 17, specifically 17q21 (Hall et al. 1990). This provided strong evidence of the 
potential existence of genes for hereditary forms of breast cancer. Following this discovery 
an international race ensued to identify and clone the breast cancer susceptibility gene, 
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which would eventually be named BRCA1 (for BReast CAncer gene 1). Three years after the 
research at UC Berkeley, the BRCA1 gene was identified using positional cloning techniques 
in samples from affected families (Bowcock 1993). Ultimately, this research allowed for the 
identification of individuals with inherited germline mutations in BRCA1. About a year after 
the BRCA1 gene discovery a second breast cancer susceptibility gene called BRCA2 (for 
BReast CAncer gene 2) was identified on chromosome 13q12.313.  While these genes are 
often referred to as cancer susceptibility genes, these genes are present in all individuals 
and in most cases the normal products of the genes play roles in preventing cancers from 
developing.  When pathogenic variants are present in these genes they can disrupt the 
normal function and thus increase risk for cancer, which is why they are called cancer 
susceptibility genes.   There are two types of DNA changes: those that are inherited and are 
present in every cell of a person’s body (germline) and those that happen after conception 
and can be contained to a specific cell line or location in a person’s body, such as a tumor 
(somatic). Inherited DNA changes can be passed down through generations because they 
are present in the cell lines of the ovary or sperm (gonads) and are referred to as germline 
alterations.  DNA changes that occur after conception in any cell(s) of a person’s body, 
excluding the gonadal cells, are referred to as somatic variants. These somatic variants, in 
combination with other factors, can, but do not always, result in cancer or other disease.   
 
Commercially available BRCA1 and BRCA2 gene sequencing was first marketed by a 
diagnostic laboratory named Myriad Genetic Laboratories, Inc in 1996. At the time Myriad 
held patents on the BRCA1 and BRCA2 genes which granted them sole control over the use 
of diagnostic sequencing tests based on those genes. Myriad began marketing three 
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principal diagnostic tests: (1) the Comprehensive BRACAnalysis, which involved full 
sequencing of the BRCA1 and BRCA2 genes, (2) the Single Site BRACAnalysis test, and (3) 
the Multisite three BRACAnalysis, three mutation BRCA1/BRCA2 analysis, which identified 
three specific pathogenic variants that are prominent in the Ashkenazi Jewish population 
(Gold et al. 2008). However, in 2013 the United States Supreme Court ruled that “A 
naturally occurring DNA segment is a product of nature and not patent eligible merely 
because it has been isolated […]” (Association for Molecular Pathology v. Myriad Genetics, 
Inc. [June 13, 2013]). This ruling prevented any future infringement complaints that Myriad 
would file against competing clinical and research laboratories.  
 
Following the Supreme Court ruling, numerous genetic testing laboratories began 
offering BRCA1 and BRCA2 gene sequencing. Since the discoveries of the BRCA1 and BRCA2 
genes, researchers have identified additional genes in which pathogenic alterations occur 
and are linked to breast and ovarian cancer susceptibility. Pathogenic variants in these 
genes do not increase the risk of breast cancer as much as pathogenic variants in the 
BRCA1/2 genes. However, pathogenic variants in these genes are linked to an increased 
risk for breast cancer in some families.  
 
The development of next-generation sequencing (NGS) allowed for more rapid and 
cost-effective gene sequencing, which facilitated the implementation of multigene panel 
testing in the clinical setting Multigene panel testing refers to sequencing multiple pre-
selected genes, not limited to BRCA1 and BRCA2, using an NGS sequencing platform. 
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Hereditary breast cancer susceptibility multigene panel testing became commercially 
available in 2012 and has since expanded to include anywhere from 5 to > 100 genes.  
 
1.1.2 Differentiating between high and moderate cancer risk genes 
 Until recently, genetic testing for cancer susceptibility focused on classic syndromes, 
such as hereditary breast and ovarian cancer (HBOC) and Lynch syndrome, which is 
associated with an increased risk of colorectal and endometrial cancer among other types 
of cancer. In the clinical setting multigene panel testing has helped identify patients and 
families who carry pathogenic variants in the ATM, BARD1, BRIP1, CHEK2, NBN, RAD50, 
RAD51C and RAD51D genes. The presence of a pathogenic variant in one of these genes can 
confer breast cancer risks that are not as high BRCA pathogenic variants but still above the 
breast cancer risk in the general population, so the genes are referred to as moderate 
breast cancer risk genes (MBRGs). Pathogenic variants in these genes usually confer a 
modest increase in breast cancer risk (relative risk 2-4) as compared to the general 
population (Couch, F.J. et al. 2017, Hollestelle, A et al. 2010, Tung et al. 2016). These 
individuals are in stark contrast to carriers of pathogenic variants in genes associated with 
a high risk for breast cancer (HBRGs). Pathogenic variants in these genes can confer a 
lifetime breast cancer risk of up to 87 percent (relative risk 5-9) (Brose MS et al. 2002, 
Kuchenbaecker KB et al. 2017, Levy-Lahad E et al. 2007, Suarez-Kelly et al. 2019). 
Numerous studies have shown that variants in MBRGs are identified between 1.1-9.4% of 
the time in individuals referred for genetic testing (Couch et al. 2015, Cragun et al. 2014, 
Kurian et al. 2014, LaDuca et al. 2014, Lincoln et al. 2015, Maxwell et al. 2015, Minion et al. 
2015, Tung et al. 2015, Walsh et al. 2011, Yurgelun et al. 2015). Management guidelines 
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exist for carriers of pathogenic variants in HBRGs, (such as BRCA1, BRCA2, CDH1, NF1, 
PTEN and TP53) although these guidelines may not apply to all patients depending on 
family history (NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and 
Ovarian 2019). There are also management guidelines available for patients with 
pathogenic variants in MBRGs such as ATM, CHEK2, NBN, and PALB2 (NCCN Guidelines for 
Genetic/Familial High-Risk Assessment: Breast and Ovarian 2019). However, to date, there 
are no consensus guidelines on how to manage breast cancer risk in patients who carry 
pathogenic variants in genes such as BARD1, BRIP1, RAD50, RAD51C, and RAD51D. It is 
important to note that the threshold for distinguishing a HBRG from a MBRG is sometimes 
left to the discretion of individual providers and genetic testing laboratories. For instance, 
in recent studies PALB2 has been suggested to be re-categorized as a HBRG but some 
clinicians and laboratories still consider it to be a MBRG (Antonis C et al. 2014, Rahman et 
al. 2007). This is because some pathogenic variants in PALB2 confer a higher risk for breast 
cancer only in certain families (Antoniou et al. 2014). Additionally, pathogenic variants in 
NF1 can be considered to cause high risk in younger women and moderate risk in older 
women (Madanikia et al. 2012, Seminog et al. 2015). For the purpose of this study, NF1 was 
considered a HBRG and PALB2 a MBRG.  
 
1.1.3 Current practices of multigene panel testing  
 
 The use of multigene panels for the assessment of hereditary cancer susceptibility is 
expanding rapidly in clinical practice. Multigene panel testing in the cancer genetics setting 
refers to sequencing with or without deletion/duplication analysis of a curated group of 
genes associated with cancer susceptibility. One survey found that 94 percent (143/152) of 
 6 
 
genetic counselors had begun implementing multigene panel testing into their practice 
(Hooker et al. 2017). However, the value of multigene-panel testing remains debatable due 
to the uncertainty regarding the strength of association between pathogenic variants in 
some genes and the development of cancer (clinical validity), and a lack of evidence 
demonstrating improved outcomes for the individuals tested (clinical utility) (Easton et al. 
2015, Domchek et al. 2013, Kurian et al. 2017). Despite this controversy, it is clear that 
multigene panel testing has become entrenched in clinics and as one oncologist put it 
“there seems little chance of forcing the genie back into the bottle” (Kurian et al. 2015).  
 
1.1.4 Genetic testing results  
 It is important for patients and providers to consider the risks and benefits 
associated with genetic testing. While there are no risks of physical harm, other than a 
blood draw, genetic testing can have unintended emotional effects, particularly when a 
pathogenic variant is found. However, there are many possible benefits of genetic testing. 
For instance, identifying a pathogenic variant can give a patient and their family members a 
better understanding of their cancer risks which can lead to increased cancer screening 
and/or risk-reducing surgeries or preventative treatments. When genetic testing is 
performed there are three possible test results: positive (pathogenic or likely pathogenic 
variant detected), negative (no clinically significant variants detected), and uninformative 
(variant of uncertain significance detected).  
 
 A positive test result means that a pathogenic variant was identified which confers 
an increased risk for certain types of cancer. A person’s individual risk for cancer depends 
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on the gene and often the specific variant that was identified. For some variants, the risks of 
specific cancers may be very high. For other variants, the risks may be lower. Even with a 
positive test result a patient’s risk for developing cancer is not 100 percent; it is possible to 
carry a pathogenic variant associated with increased cancer risk and never develop cancer. 
A positive test result may affect treatment decisions for patients with cancer and can affect 
screening and risk-reducing options for individuals who have not developed cancer. A 
positive test result also has serious implications for family members. Variants in genes 
associated with hereditary cancer susceptibility can be inherited. For the majority of these 
genes, there is a 50% chance that a person who carries a variant will pass it to each of their 
children. Therefore, it is important for patients to discuss their positive test results with 
their genetic counselor or health care team.  
 
A negative test result means that no pathogenic variant was identified in the gene(s) 
analyzed. There are several reasons why someone might receive a negative result 
including: (1) an individual could have a variant in an analyzed gene that cannot be 
identified by the current testing method, (2) an individual could have a variant in a 
different gene that was not included in the testing, (3) an individual’s cancer is not due to 
an inherited gene variant.  In many cases sequencing alone cannot detect large deletions or 
duplications in the genome and therefore an additional testing methodology must be 
performed to identify these types of variants.  Historically this additional methodology was 
not routinely performed so some individuals who had “negative” testing may actually carry 
a pathogenic variant.  In addition to improved BRCA1/2 pathogenic variant detection with 
deletion and duplication analysis, current hereditary cancer susceptibility testing includes 
 8 
 
non-BRCA1/2 genes associated with an increased risk of developing cancer. Patients with 
previous negative results from genetic testing that only included BRCA1/2 may still be at 
risk to carry a pathogenic variant and may want to consider multigene panel testing. 
Finally, patients with a negative test result may not have an inherited genetic cause for 
their personal and/or family history of cancer. It is important to note that inherited genetic 
variants play a role in only five to ten percent of all breast cancers (American Cancer 
Society. Breast Cancer Facts & Figures 2015-2016). Therefore, a majority of patients who 
undergo genetic testing will not have an inherited pathogenic variant identified.  
 
The final, and at times most disconcerting, type of test result is an uninformative 
test result, e.g., a variant of uncertain significance. In other words, there is a change in the 
sequence of a gene, but there is insufficient evidence to conclude whether it is disease 
causing or part of the spectrum of benign variation in the human population.  Genetic 
variants can be classified as variants of uncertain significance for a myriad of reasons 
including: lack of phenotypic evidence associated with the variant, conflicting evidence, or 
rarity in the general population. A variant of uncertain significance is deemed 
uninformative because it will not add any additional information to the clinical assessment 
of cancer risk and therefore risk estimates must be made based on personal and family 
medical history. It is important for individuals who are identified as carriers of a variant of 
uncertain significance to stay in contact with their genetics specialist in the event that their 
variant is reclassified to pathogenic, likely pathogenic, likely benign or benign variant.  
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1.1.5 Multigene panel testing leads to increased identification of variants of uncertain 
significance (VUSs)  
 Clinical utility remains the fundamental issue with multigene panel testing, 
particularly for variants identified in MBRGs. One claim against clinical utility is the 
increase in identification of variants of uncertain significance (VUS) concomitant with an 
increase in the number of genes on a panel. It has been well established that multigene 
panel testing, compared with traditional single gene testing, increases the VUS rate, mainly 
as a result of sequencing non-BRCA1/2 genes (Chong et al. 2014, Kapoor et al. 2015, Kurian 
et al. 2014, LaDuca et al. 2014, Slavin et el. 2015, Tung et al. 2015). The likelihood of a VUS 
result is even higher for individuals from non-Caucasian populations due to insufficient 
information on the common benign genetic variation in those populations (Hall et al. 
2009). This lack of information is due in part to the disproportionate overrepresentation of 
people of European ancestry in reference genetic databases. Additionally, one study found 
that BRCA1/2 reclassification rates varied by ancestry and increased over time; the rates 
increased more steeply for people of African, Ashkenazi, and Chinese ancestry (Slavin et al. 
2018).  
 
1.1.6 Identification of VUSs cause anxiety and distress for providers and patients   
 Due to the uninformative nature of variants of uncertain significance, both patients 
and clinicians can experience confusion and anxiety regarding test result interpretation 
and associated health recommendations. One study found that even with genetic 
counseling, patients with a VUS result reported higher cancer distress as compared to 
patients with a negative test result (Culver et al. 2013). In addition to increased stress, it 
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has been shown that patients with a VUS result fail to recall the clinical significance of their 
result approximately one-third of the time (Richter et al. 2013). The confusion surrounding 
VUSs is not limited to patients; numerous studies have shown inappropriate interpretation 
of uninformative results among non-genetics providers (Macklin et al. 2018, Keating et al. 
2008, Welsh et al. 2017, Kurian et al. 2017). Macklin et al. found that, when surveyed about 
how comfortable providers feel discussing genetics in their practice, 25% of respondents 
reported feeling uncomfortable, 24% somewhat uncomfortable, 34% somewhat 
comfortable, and only 15% comfortable (Macklin et al. 2018). Additionally, the study found 
that nearly 60% (54/91 respondents) did not feel comfortable explaining a VUS to their 
patient.  
 
The misinterpretation of a VUS result could lead to unnecessary treatment, surgery, 
anxiety and/or false reassurance. The genetics community is in agreement that testing 
affected relatives for a VUS, unless it is in the context of a research study, is not 
recommended (Richards et al. 2015). Testing relatives can lead to unnecessary care or a 
false sense of reassurance if the VUS is not detected. VUS-related anxiety is due in part to 
rapid advances in genetic testing and integration that many non-genetics providers feel 
unequipped to keep up with (Najafzadeh et al. 2012). While comfort is likely to increase 
with clinical exposure, it is also important to actively increase non-genetics providers’ 
knowledge of genetics. 
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1.1.7 Historical and current published standards and guidelines for the interpretation of 
sequence variants 
 The widespread implementation of next-generation sequencing in clinical care has 
highlighted the importance of standardizing the interpretation and reporting of genetic test 
results across laboratories. As previously discussed genetic testing may have positive, 
negative, or uninformative results. The correct interpretation of variants is crucial to the 
clinical validity and utility of genetic testing. Simultaneous multigene sequencing in the 
clinical setting did not become widely available until the advent of high-throughput 
sequencing technologies which allowed for faster turn-around times and less cost. A 
majority of DNA sequence changes that result in an increased risk of developing cancer are 
pathogenic variants which disrupt the function of the gene. For example, BRCA1/2 are 
tumor suppressor genes, meaning these genes encode for proteins that help control and 
regulate cell growth. Inactivation of tumor suppressor genes, via pathogenic variants, leads 
to uncontrolled cell growth which precipitates tumor development. Alternatively, 
activating pathogenic variants in proto-oncogenes, such as MET, which promote cell 
growth cause the gene to become permanently activated. This permanent activation causes 
cells to divide out of control, which leads to tumor development.  
 
 In 2007 practice guidelines were proposed for classification of variants as a joint 
action of the Dutch and British societies for clinical molecular genetics (Bell et al. 2007). 
These guidelines helped establish quality standards and lines of evidence which could be 
utilized when assessing whether or not a variant might be pathogenic. These practice 
guidelines conclude that it is essential to report all sequence variants and proposed 
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reporting uncertain variants in three classes: a) certainly not pathogenic; b) unlikely to be 
pathogenic; and c) likely to be pathogenic. However, this classification scheme is not 
currently used by commercial laboratories in the United States. Around the same time, the 
American College of Medical Genetics (ACMG) published recommendations in 2008 which 
included 6 interpretative categories of sequence variations for the purposes of clinical 
reporting (Richards et al. 2008). More recently, ACMG published updated standards and 
guidelines for the classification of sequence variants using criteria informed by expert 
opinion and empirical data (Richards et al. 2015).  
 
 The current joint guidelines published by ACMG and AMP include five classification 
categories in order of decreasing clinical significance: pathogenic, likely pathogenic, VUS, 
likely benign, benign. The guidelines defined 28 criteria that address evidence such as 
population data, case-control analyses, functional data, computational predictions, allelic 
data, segregation studies, and de novo observations. Each pathogenic criterion is weighted 
as very strong (PVS1), strong (PS1–4); moderate (PM1–6), or supporting (PP1–5), and each 
benign criterion is weighted as stand-alone (BA1), strong (BS1–4), or supporting (BP1-6). 
It is important to note that the numbering within each evidence category does not convey 
any differences of weight and is merely assigned to help refer to the different criteria. The 
criteria weight and direction are combined to arrive at one of the five classifications. For 
example, a variant that causes a nonsense or frameshift mutation in a gene where loss of 
function (LOF) is a known mechanism of disease is very strong evidence towards 
pathogenic classification (PVS1). A complete list of the ACMG-AMP criteria for classifying 
pathogenic and benign variants can be found in Appendix A. ACMG-AMP guidelines also 
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introduced a uniform nomenclature of variants to enable effective sharing and future use of 
genomic information. A standard gene variant nomenclature 
(http://www.hgvs.org/mutnomen) is maintained and versioned by the Human Genome 
Variation Society (HGVS). Due to the complex and evolving nature of variant analysis and 
interpretation ACMG-AMP strongly recommend that clinical molecular genetic testing be 
performed at a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory 
with results being interpreted by a board-certified clinical molecular geneticist or 
equivalent.   
 
1.1.8 Commercial laboratory variant assessment and classification scheme  
 Once a genetic variant is detected in the laboratory, its clinical significance must be 
determined. Although there are published standards and guidelines for the interpretation 
of sequence variants, adherence to these standards and guidelines is entirely voluntary and 
does not necessarily assure an accurate classification. Clinical laboratories have created, 
and in some instances published, their own classification schemes. Individual laboratory 
classification schemes often have significant overlap with the ACMG-AMP criteria. The 
variant classification scheme used for this study is detailed in Appendix B and published 
online by Ambry Genetics 
(https://www.ambrygen.com/file/material/view/272/Variant_ClassificationScheme_0617
_Final.pdf). The scheme is an adapted version of the previously published ACMG-AMP 
standards and guidelines for the interpretation of sequence variants (Richards S et al. 
2015). Genetic testing laboratories will often share the variant classification information if 
an inquiry is made. In addition to having a documented classification scheme, each 
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laboratory will have a documented variant review process.  The variant review process 
generally involves collaboration between statisticians, bioinformaticians, variant scientists, 
structural biologists, genetic counselors and lab directors. Each of these individuals offers a 
unique perspective on variant analysis and interpretation. Most commercial laboratories 
offer varied approaches to VUS resolution including but not limited to proprietary variant 
databases, segregation studies, and collaboration with variant experts. Although the 
sequencing technology used across laboratories is similar, laboratories have individual VUS 
and reclassification rates. If a discrepant variant classification exists between laboratories, 
there is a working group hosted by an organization named ClinGen called “Sequence 
Variant Inter-Laboratory Discrepancy Resolution” which aims to resolve the discrepant 
variant classification. As of this year there are 19 commercial genetic testing laboratories 
that participate in this process (https://clinicalgenome.org/working-groups/sequence-
variant-inter-laboratory-discrepancy-resolution/). One study found that nine laboratories 
who were asked to classify variants using either the ACMG-AMP system or their own 
criteria were in agreement on calls about one-third of the time (33/99) (Amendola et al. 
2016). However, after either emails or conference calls among the reporting laboratories 
they were able to agree on 71% of calls (70/99).  While this data is encouraging, this level 
of collaboration is not feasible for every variant call. 
 
1.1.9 Importance of accurate variant classification 
 To facilitate accurate and uniform classification, laboratories are encouraged to 
share evidence and internal data used for classification when applicable. Similar to 
misinterpretation of a VUS result the inaccurate classification of a VUS can lead to 
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unnecessary treatment or surgery, anxiety and/or false reassurance (Makhnoon et al. 2019, 
O’Neill C. et al. 2009). Previous studies have shown a majority of VUS reclassifications are 
downgrades to less severe classifications, but VUS reclassification to pathogenic variant or 
likely pathogenic variant can lead to drastic medical management changes that accompany 
serious implications for patients (Macklin et al. 2018, Mersch et al. 2018). For example, 
management for women with a pathogenic variant in BRCA1/2 can include a variety of 
options from high-risk surveillance to prophylactic removal of the ovaries and/or breasts. 
With the implementation of genetic testing into the medical management paradigm there is 
a risk for inaccurate variant calling and/or variant reclassification.  
 
1.1.10 Prevalence of variant reclassification following hereditary cancer genetic testing  
 As previously discussed, the clinical implications of accurate variant interpretation 
are substantial. Therefore, it is crucial that new data and research related to variant 
interpretation for cancer-risk genes is reviewed by genetic testing laboratories on a 
periodic and consistent basis. One study analyzed variant reclassifications for individuals 
who underwent single-syndrome or multigene panel cancer genetic testing for hereditary 
cancer predisposition at a single laboratory over a 10-year period (Mersch J et al. 2018). 
They found that of the 26,670 unique VUSs reported during that time period, 2,048 (7.7%) 
were reclassified, which lead to 24.9% of the cohort receiving an amended clinical report. 
Importantly, the overwhelming majority (91.2%) of the VUSs were downgraded to benign 
variant or likely benign variant. Another study analyzed test reports of patients tested at 
the Mayo Clinic in Florida between September 2013 and February 2017 and found that 
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11.3% (30/266) of the VUSs were reclassified (Macklin et al. 2018). Again, a majority 
(around 75%) of the reclassified VUSs were downgraded to likely benign.  
 
 Overall, the evidence to date suggests that most VUS reclassifications are 
downgrades to likely benign or benign. However, in the event of a VUS being upgraded to 
pathogenic or likely pathogenic, a patient’s individual cancer risks and management 
strategies should be discussed with their care team. Sharing of data and variant 
classifications between laboratories can increase knowledge on how specific genetic 
variants impact a patient’s health. 
 
Given the possibility of a VUS being reported in a gene for which cancer risks are not 
well-defined, several registries have been created to catalog and curate these variants with 
the goal of advancing our knowledge about their clinical utility. The Prospective Registry of 
Multiplex Testing (PROMPT) is a multi-institutional online registry that encourages 
patients to self-enter information about their genetic testing results and to complete 
questionnaires about their personal medical and family histories 
(http://promptstudy.info/). Other resources related to variant classification include 
ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) 
Consortium and ClinVar, a peer-reviewed database funded by the National Institutes of 
Health, which is a freely available archive of reports of relationships among medically 
important variants and phenotypes. Multiple professional societies have adopted positions 
in favor of data sharing (American Medical Association 2013, National Institutes of Health 
2014, National Society of Genetic Counselors 2015, ACMG Board of Directors 2017). 
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1.2 Purpose of Study and Specific Aims  
  Using a retrospective database review of variant reclassifications in 15 breast 
cancer predisposition genes from January 2014 to January 2018, this study aims to identify 
and compare the criteria used for reclassification of VUSs in HBRGs and MBRGs. 
Additionally, this study aims to compare the triggers that lead to reclassification of VUSs in 
HBRGs and MBRGs. I hypothesize that there will be a significant difference in the criteria 
used for VUS reclassification when comparing HBRGs and MBRGs. I hypothesize that these 
differences are likely due to the availability of specific criteria, such as functional data, as 
well as the prevalence of certain variants. I also hypothesize that there will be a significant 
difference seen when looking at the triggers that lead to VUS reclassification when 
comparing HBRGs and MBRGs; because implications of a pathogenic variant in a HBRG are 
more likely to significantly impact clinical management than are pathogenic variants in a 
MBRG, clinicians may be more motivated to push for reclassification of variants in HBRGs.  
 
 This study will also examine and quantify the time between original VUS 
classification and reclassification. I hypothesize that there will be a significant difference in 
time to reclassification for variants in HBRGs versus MBRGs. I predict time to 
reclassification for VUSs in HBRGs will be significantly shorter than that in MBRGs.  An 
additional aim of this study will be to highlight the importance of specific criteria such as 
functional studies, family studies and clinical phenotypes towards VUS reclassification. 
Finally, the overall purpose of this study is to provide a better understanding of the variant 
reclassification process for patients and healthcare providers.  
 
 18 
 
II. METHODS 
2.1 IRB approval  
  This study was determined to be non-human subject research by the University of 
California, Irvine (UCI) Institutional Review Board (IRB) under application HS#: 2018-
4835 (Appendix C).  
 
2.2 Collection of VUS reclassifications over study period  
  Individual variants were queried and collected by the lead author using a 
proprietary DNA sequence variant database from a single commercial genetic testing 
laboratory, Ambry Genetics, from January 2014 to January 2018. The variants analyzed 
are stored in a secure proprietary database that is accessible only by password-protected 
log-in. Each variant is annotated with relevant meta-data, including information on 
variant genomic location, evidence supporting classification, nucleotide alignment, 
disease information, population frequency, etc.  
  
  Variants were included if they were identified in one of 15 breast cancer 
predisposition genes and were reclassified from VUS to either pathogenic, VLP, VLB, or 
benign during the aforementioned time period. The genes included were separated into 
two breast cancer risk categories; high (HBRGs) and moderate (MBRGs). HBRGs included 
BRCA1, BRCA2, CDH1, NF1, PTEN, TP53; associated cancer risks range from 5-9 times that 
of the general population (Brose MS et al. 2002, Kuchenbaecker KB et al. 2017, Levy-
Lahad E et al. 2007, Suarez-Kelly et al. 2019). MBRGs included ATM, BARD1, BRIP1, 
CHEK2, NBN, PALB2, RAD50, RAD51C, and RAD51D; associated cancer risks range from 2-
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4 times that of the general population (Couch, F.J. et al. 2017, Hollestelle, A et al. 2010, 
Tung et al. 2016). The variants included were identified in patients in whom clinical 
genetic testing was ordered by a health care provider and performed between 2012 and 
2017. These variants were then further queried to identify those with a non-VUS 
classification as of February 2019. A complete list of all VUSs that were reclassified 
between January 2014 and January 2018 was generated and each variant was 
determined to have an outcome of either upgrade or downgrade. An upgrade was defined 
as a VUS being reclassified to either a likely pathogenic or pathogenic. A downgrade was 
defined as a VUS being reclassified to a likely benign or benign. In total 900 variants met 
these inclusion criteria and were available for review. This number reflects all of the 
VUSs that were reclassified from January 2014 to January 2018. Any variant that was 
reclassified outside of the specified time period or was reclassified for less than 24 hours 
was disqualified and not included in the data set. A total of 283 variants were excluded on 
the basis of these criteria, leaving 617 variants. 
 
2.3 Collection of VUS reclassification drivers and triggers    
A data collection sheet was generated to review each reclassified variant, and only 
this data collection sheet was used for subsequent analyses. No protected health 
information (PHI) was documented on the data collection sheet. For each variant the 
following information was collected: gene name, coding DNA sequence change(c.), 
predicted protein sequence change (p.), variant classification as of February 2019, 
original VUS classification date, reclassification date, reclassification trigger, 
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reclassification criteria (driver), and discrepant classification in a public variant database 
(ClinVar)( https://www.ncbi.nlm.nih.gov/clinvar/). 
 
Using ACMG-AMP guidelines and documented internal laboratory procedures for 
adaption to hereditary cancer predisposition testing, the category of evidence and 
criteria used for reclassification was documented (Appendix A). The evidence categories 
consisted of very strong evidence for pathogenicity (PVS1), strong to moderate evidence 
for pathogenicity (PS1-4, PM1-6), supporting evidence for pathogenicity (PP1-5), very 
strong evidence for benign (BA1), strong to moderate evidence for benign (BS1-4), and 
supporting evidence for benign (BP1-6). There are specific criteria that are assigned to 
each evidence category, for example, in very strong evidence for pathogenicity the 
following criteria is listed: Null variant (nonsense, frameshift, canonical ±1 or 2 splice 
sites, initiation codon, single or multiexon deletion) in a gene where loss of function is a 
known mechanism of disease. In each evidence category there is a criterion that states 
“Other […] data supporting […] classification.” If this criterion was cited more details 
were collected regarding the “other data”. For example, a number of variants were 
reclassified due to updates in classification evidence and/or weighting which was 
documented as “other data” criteria. A complete list of “other” criteria is listed in 
Appendix D.  
 
The event that triggered the reclassification process was also documented for each 
variant. There are several events that can trigger the reclassification process including 
but not limited to: availability of new research or data, periodic re-review of evidence, or 
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provider request. A complete list of all the reclassification trigger categories investigated 
is available in Appendix E.  
  
The error rate of collected data was determined by randomly selecting 11.2% of the 
variants for re-collection. All data on 69 variants (randomly distributed across all 15 genes) 
were re-collected for all variables. Initially collected variant data was compared to re-
collected data to determine the data collection error rate.  
 
2.4 Data Analysis  
 Data was analyzed using qualitative and quantitative analyses techniques. 
Frequencies of variant information were calculated for categorical and binomial variables 
using Microsoft® Office Excel. Chi-square values were calculated using IBM SPSS®. Logistic 
regression analysis was performed using RStudio. For all statistical analyses p<0.05 were 
considered statistically significant.  
 
2.4.1 VUS reclassification direction over study period 
 A chi-square test was performed to determine if there was a significant association 
between gene category (HBRG or MBRG) and VUS reclassification direction (upgrade or 
downgrade). The number of upgrades and downgrades seen each year was calculated and 
was further stratified by category of gene, HBRG or MBRG. A logistic regression model was 
used to quantify the strength of the association between reclassification outcome (upgrade 
or downgrade) and the independent variate of reclassification year (2014, 2015, 2016 or 
2017), separately for reclassified variants in HBRGs and MBRGs. It was assumed that every 
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variant in each year had an equal opportunity for reclassification. Downgrade was coded as 
the reference level and upgrade was the outcome of interest. For each group of cancer risk 
genes, HBRG and MBRG, the odds ratio of upgrade was reported along with a 95% 
confidence interval and corresponding p-value. The odds ratio was considered to be 
statistically significant if the confidence interval excluded the value 1, or equivalently if 
p<0.05. The year 2018 was excluded from the regression analysis due to low counts (n=7). 
A summary of the logistic regression model is provided in Appendix F. 
 
2.4.2 Frequency of discrepant classification 
Each reclassified variant was queried in a public variant database, ClinVar, to 
determine if there was a discrepancy between the variant call in the dataset and the call 
made by at least one other laboratory that was present in ClinVar as of February 2019.  The 
presence of at least one discrepant classification from another laboratory was counted as 
discrepant, regardless of the number of other concordant classifications. The frequency of 
discrepant classification was quantified as well as the level of discrepancy. If the 
commercial laboratory that provided the variant information for this study called a variant 
likely benign and another laboratory in ClinVar called the variant a VUS or benign, this was 
counted as one level of discrepancy. The levels of discrepancy collected included 1, 2, and 3.  
 
2.4.3 Differences in time to VUS reclassification 
Time to reclassification was calculated from date of initial classification as a VUS to 
date of variant reclassification. For reclassified variants in HBRGs and MBRGs minimum 
value, maximum value, and mean were calculated to generate a box and whisker plot. 
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Additionally, an independent t-test was performed to analyze and compare average time to 
VUS reclassification in HBRGs versus MBRGs. 
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III. RESULTS 
 
 
3.1 Direction of VUS reclassification over study period  
 A retrospective variant database review of VUSs that were reclassified from January 
2014 to January 2018 was conducted to quantify if there was a difference in the 
reclassification direction as well as if there were any differences in the criteria used for 
reclassification depending upon the risk category of the gene (HBRG or MBRG). A total of 
617 variants in 15 genes that were reclassified between January 2014 and January 2018 
were reviewed. 
Figure 1. Overall distribution of VUS reclassifications.  A) Green colors indicate variant downgrades; 
red colors indicate variant upgrades. Percentage reflects percentage of total reclassified variants. B) 
Shades of red reflect variants that were upgraded to either likely pathogenic (dark red) or pathogenic 
(light red). Percentage reflects percentage of total variants that were upgraded. C) Shades of green 
indicate variants that were downgraded to either likely benign (dark green) or benign (light green). 
Percentage reflects percentage of total variants that were downgraded.  
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The majority of reclassifications were downgrades, 81% (498/617) (Figure 1). 
Within the downgrades almost all of the variants were downgraded to VLB, 94% 
(468/498). Within the upgrades the majority of the variant reclassifications were to VLP, 
84% (100/119).  
 
 BRCA2 had the greatest number of reclassified variants (195/640), followed by 
BRCA1 (100/640) (Figure 2). Reclassified variants in MBRGs made up about 28% 
(220/617) of the total reclassifications. Reclassified variants in HBRGs accounted for the 
rest of the reclassifications, about 71% (397/617). 
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Figure 2. Gene specific distribution of VUS reclassifications.  Blue colors indicate 
HBRGs; yellow colors represent MBRGs.  Percentage reflects percentage of total 
reclassified variants.  
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The number of upgrades and downgrades of reclassified variants in HBRGs and 
MBRGs were compared (Figure 3.1). For reclassified variants in both HBRGs and MBRGs a 
majority of reclassifications resulted in downgrades (79% and 83%, respectively). There 
was no statistically significant difference in the number of variants upgraded or 
downgraded when comparing reclassified variants in HBRGs and MBRGs.  
 
Additionally, the frequency of upgrades and downgrades was further calculated for 
each gene. Nearly all (14) of the genes included had a higher frequency of variant 
downgrades (Figure 3.2). Only one gene, PTEN, was shown to have a higher frequency of 
variant upgrades, 53% (8/15). In particular, the genes with the highest reclassified variant 
Figure 3.1 Upgrade and downgrade frequency of VUSs in HBRGs and MBRGs. N equals the 
number of variants in each group. Percentages reflect percentage of HBRGs and MBRGs 
respectively.  
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counts, BRCA1 (100/617) and BRCA2 (195/617) showed variant downgrade frequencies of 
75% or higher. Two genes, BARD1 and NBN, exclusively had variant downgrades.  
 
The upgrade and downgrade frequency for reclassified VUSs in HBRGs and MBRGs 
was further analyzed by year of reclassification (Figure 4.1 and Figure 4.2). For reclassified 
VUSs in HBRGs the highest incidence of upgrades was in the year 2017, with 33% of 
reclassifications that year being upgrades (42/129). Alternatively, the year 2014 had the 
lowest incidence of upgrade for reclassified variants in HBRGs (8%, 7/86). The largest 
difference in frequency of upgrades between consecutive years was seen between 2016 
and 2017 with a difference of 13%.  
Figure 3.2 Frequency of VUS reclassification upgrade or downgrade per gene. Green colors indicate 
downgrades; red colors represent upgrades. N equals the number of variants in specified gene. Percentages 
reflect percentage of upgrades and downgrades of variants in specified gene.  
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For reclassified variants in MBRGs, the highest incidence of upgrades was seen in 
the year 2017 at 21% (17/82), with the year 2015 following closely behind at 20% (8/40). 
The years 2014 and 2016 had the lowest incidence of upgrades at 11% each (2/18 and 
8/76 respectively).  
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Figure 4.1 Frequency of VUS upgrade and downgrade in HBRGs per year. N equals 
the number of reclassified variants in each year. Percentages reflect percentage of all 
reclassification upgrades and downgrades in specified year.  
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Logistic regression was used to model the odds of variant upgrade based on the year 
of variant reclassification, with separate models generated for HBRGs and MBRGs.  The 
regression models showed an increase in the odds of upgrade for VUSs that were 
reclassified over the specified period (January 2014 to December 2017) (Table 1.1 and 
Table 1.2). The odds of upgrade for reclassified VUSs in HBRGs were 1.68 times higher each 
year of the study (CI 1.33 - 2.13).  For reclassified VUSs in MBRGs, the odds of upgrade 
were 1.17 times higher each year but this finding was not statistically significant (CI 0.79 - 
1.74). 
  
Figure 4.2 Frequency of VUS upgrade and downgrade in MBRGs per year. N 
equals the number of reclassified variants in each year. Percentages reflect percentage 
of all reclassification upgrades and downgrades in specified year.  
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Table 1.1  Logistic regression analysis for VUS reclassification in HBRGs.  
Independent variable Z value p OR (upgrade) 95% CI 
Year of Reclassification 4.28 <0.001 1.68 1.33 – 2.13 
 
Table 1.2  Logistic regression analysis for VUS reclassification in MBRGs.  
Independent variable Z value p OR (upgrade) 95% CI 
Year of Reclassification 0.783 0.433 1.17 0.79 – 1.74 
 
3.2 Criteria used in VUS reclassification 
One aim of this study was to quantify the criteria used for VUS reclassification. Table 
2 details the criteria cited most frequently for VUS reclassification. The most common 
criteria cited were in the “strong to moderate evidence” for benign category, 43.6% 
(269/617). Within this evidence category, the criteria cited most often was 
“BP4_strong/BS1 Other strong data supporting benign classification” (222/617) with 
“BP2_strong Observed in trans with a pathogenic variant for a fully penetrant dominant 
gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern” 
being cited second most frequently (28/617). “Supporting evidence for benign” was the 
second most frequent evidence category cited at 36.1% (223/617). Within this evidence 
category, “BP6/BP4_strong/BS4/BS4_supporting Other data supporting benign 
classification” was cited most frequently at 10.5% (65/617).  The third evidence category 
cited most often was “strong to moderate evidence” of pathogenicity at 17.2% (106/617). 
“PM1/5 Other moderate data supporting pathogenic classification” was the criteria cited 
most frequently within this evidence category at 5.3% (33/617). Criteria referred to as 
 31 
 
“[…] Other […]” was frequently cited for VUS reclassification. Table 3 shows the frequency 
and further details of “other” data cited.  
 
 
 Evidence Category & Criteria  
 
2014 to 2018 
(n=617) 
n (%)  
P
a
th
o
g
e
n
ic 
Very Strong Evidence  1 (0.2%) 
PVS1 In-frame gross deletion with loss of an important functional 
domain 
 1 (100%) 
Strong to Moderate Evidence  106 (17.2%) 
PS2/PM6 De novo (both maternity and paternity confirmed) in a 
patient with the disease and no family history or assumed de novo, 
but without confirmation of paternity and maternity  
10 (1.6%) 
PS3 Well-established in vitro or in vivo functional studies 
supportive of a damaging effect on the gene or gene product 
(splicing alteration) 
15 (2.4%) 
PS4 The prevalence of the variant in affected individuals is 
significantly increased compared with the prevalence in controls 
0 (0%) 
PP4 Patient’s phenotype or family history is highly specific for a 
disease with a single genetic etiology  
17 (2.8%) 
PVS1_strong/ PVS_ moderate Last nucleotide of exon  0 (0%) 
PP1_strong Cosegregation with disease in multiple affected family 
members in a gene definitively known to cause the disease  
3 (0.5%) 
PS3_moderate Well-established in vitro or in vivo functional studies 
supportive of a damaging effect on the gene or gene product  
25 (4.1%) 
PM5 Novel missense change at an amino acid residue where a 
different missense change determined to be pathogenic has been 
seen before  
2 (0.3%) 
PM1/5 Other moderate data supporting pathogenic classification   33 (5.3%) 
PVS1_strong/ PVS1_moderate Alterations at the canonical 
donor/acceptor sites without other strong evidence supporting 
pathogenicity 
1 (0.2%) 
L
ik
e
ly
 P
a
th
o
g
e
n
ic (V
L
P
) 
Supporting Evidence  11 (1.8%) 
PM2 Absent from controls in Exome Sequencing Project, 1000 
Genomes Project, or Exome Aggregation Consortium  
0 (0.0%) 
PP3 Multiple lines of computational evidence support a deleterious 
effect on the gene or gene product (conservation, evolutionary, 
splicing impact, etc.)  
0 (0.0%) 
PP1_moderate Cosegregation with disease in multiple affected 
family members in a gene definitively known to cause the disease  
0 (0.0%) 
PM1_supporting Other data supporting pathogenic classification 
 
 
11 (1.8%) 
Table 2. Distribution of criteria used for VUS reclassification. N equals the number of variants 
included in the study. Percentages reflect percentage of total evidence used. This chart has been modified 
from La Duca et al. 2015 
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L
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 (V
L
B
) 
Supporting Evidence  223 (36.1%) 
BS3 Intact protein function observed in appropriate functional 
assay(s) 
19 (3.1%) 
BP2 Co-occurrence with mutations in the same gene (phase 
unknown) 
52 (8.4%) 
BP5 Variant found in a case with an alternate molecular basis for 
disease  
17 (2.8%) 
BS1_supporting Allele frequency is greater than expected for 
disorder, but not statistically significant  
52 (8.4%) 
BP4 Multiple lines of computational evidence suggest no impact on 
gene or gene product (conservation, evolutionary, splicing impact, 
etc.)  
1 (0.2%) 
BS4_supporting Lack of segregation in affected members of a family 
in gene with incomplete penetrance  
11 (1.8%) 
No disease association in a small case-control study 6 (1.0%) 
BP6/BP4_strong/BS4/BS4_supporting Other data supporting benign 
classification 
65 (10.5%) 
Strong to Moderate Evidence 269 (43.6%) 
BS3 Well-established in vitro or in vivo functional studies show no 
damaging effect on protein function or splicing  
19 (3.1%) 
BP2_strong Observed in trans with a pathogenic variant for a fully 
penetrant dominant gene/disorder or observed in cis with a 
pathogenic variant in any inheritance pattern  
28 (4.5%) 
BP4_strong/BS1 Other strong data supporting benign classification 222 (36.0%) 
B
e
n
ig
n
 
Very Strong Evidence  7 (1.1%) 
BA1 Allele frequency is >5% in Exome Sequencing Project, 1000 
Genomes Project, or Exome Aggregation Consortium  
2 (0.3%) 
BS4 Lack of segregation in affected members of a family in gene 
with complete penetrance  
0 (0.00%) 
BA1/BS1 Allele frequency is greater than expected for disorder and 
is statistically significant  
3 (0.5%) 
No disease association in appropriately sized case-control 
study(ies) 
2 (0.3%) 
 
“[…] Other […]” was the criteria cited most often. Parsing this data further, we see 
that “BP4_strong Amino acid is reference allele in ≥3 primates OR ≥15 mammals” was the 
criteria cited most often at 63.1% (209/331). “BP6 Reputable source recently reports 
variant as benign, but the evidence is not available to the laboratory to perform an 
independent evaluation” was cited second most often at 17.2% (57/331). The third criteria 
cited most often was “PM1/5 Computational data, including structural analysis and/or 
modeling” at 7.6% (25/331).   
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Table 3. Distribution of “Other” evidence used in VUS reclassifications. Bolded percentages, rounded to 
the nearest tenth, reflect percent of the total variants. Non-bolded percentages, rounded to the nearest tenth, 
reflect percent of each bolded category. N equals the number of variants. 
 
Criteria Cited 2014 to 2018 
(n=331) 
n (%)  
Other moderate data supporting pathogenic classification 33 (10.0%) 
PM1/5 Mutational hotspot, computational data, including structural 
analysis and/or modeling 
25 (75.8%) 
Updated classification evidence and/or weighting 8 (24.2%) 
Other data supporting pathogenic classification 11 (3.3%) 
PM1_supporting Computational data, including structural analysis 
and/or modeling 
11 (100.0%) 
Other strong data supporting benign classification 222 (67.1%) 
BP4_strong Amino acid is reference allele in ≥3 primates OR ≥15 
mammals  
209 (94.1%) 
BS1 Internal allele frequency greater than expected  based on disease 
prevalence 
3 (1.4%) 
Updated classification evidence and/or weighting 10 (4.5%) 
Other data supporting benign classification 65 (19.6%) 
BP6 Reputable source recently reports variant as benign, but the 
evidence is not available to the laboratory to perform an 
independent evaluation 
57 (87.7%) 
BP4_strong Amino acid is reference allele in ≥3 primates OR ≥15 
mammals 
3 (4.6%) 
BP4 Computational data, including structural analysis and/or modeling 3 (4.6%) 
BS4_supporting Multifactorial models using likelihood ratio of 
pathogenicity for segregation*  
2 (3.1%) 
*International Agency for Research on Cancer (IARC) and Open Variation Database (LOVD) 
(https://www.lovd.nl/) 
  
 
Within each evidence category, i.e. very strong evidence, moderate evidence, 
supporting evidence, etc., a comparison between HBRGs and MBRGs was performed. There 
was no significant difference in the frequency of criteria used in the evidence category 
“Very strong evidence for pathogenicity” between reclassified variants in HBRGs and 
MBRGs. A statistically significant difference was seen for two criteria cited in the “Strong to 
moderate evidence of pathogenicity” evidence category “PS2/PM6” and “Updated 
classification evidence and/or weighting” (p=0.033 and p=0.042 respectively). “PS2/PM6 
De novo in a patient with the disease and no family history”, was never cited as criteria for 
reclassification for variants in MBRGs (0%).  
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A chi-square test was performed for evidence category “Strong to moderate 
evidence for benign” to analyze differences between reclassified variants in HBRGs and 
MBRGs. “Updated classification evidence and/or weighting” was cited significantly more 
often for reclassified variants in HBRGs (6%) as compared to reclassified variants in 
MBRGs (1%) (p=0.040). Of note, “BP4_strong Amino acid is reference allele in ≥3 primates 
OR ≥15 mammals” was cited frequently for reclassified variants in both HBRGs and MBRGs.  
All other criteria cited in this evidence category were not found to have a statistically 
significant difference in frequency.  
Figure 5. Frequency of “strong to moderate evidence of pathogenicity” used for VUS 
reclassification in HBRGs and MBRGs. N equals the number of variants. Percentages reflect 
frequency of criteria used for each category of genes.  P-values in bold indicate statistical 
significance.  
‡: Updated classification evidence and/or weighting 
*See Table 2 for a full description of ACMG evidence criteria codes  
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A chi-square test was performed for evidence category “Supporting evidence for 
benign” to analyze differences between reclassified variants in HBRGs and MBRGs. Three 
criteria showed statistically significant differences in frequency between reclassified 
variants in HBRGs and MBRGs; “BS1_supporting”, “BP6”, and “BS3” (p<0.001 for both BS1 
and BP6; p=0.021 for BS3). “BS1_supporting Allele frequency is greater than expected for 
disorder” was cited more frequently for reclassified variants in MBRGs (56%) as compared 
to reclassified variants in HBRGs (10%). Alternatively, “BP6 Reputable source recently 
Figure 6. Frequency of “strong to moderate evidence for benign” used for VUS 
reclassification in HBRGs and MBRGs.  N equals the number of variants. Percentages reflect 
frequency of criteria used for each category of genes.  P-values in bold indicate statistical 
significance. 
‡: Updated classification evidence and/or weighting 
*See Table 2 for a full description of ACMG evidence criteria codes 
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reports variant as benign, but the evidence is not available to the laboratory to perform an 
independent evaluation” was cited solely for reclassified variants in HBRGs (37%). Finally, 
“BS3 Well-established in vitro or in vivo functional studies show no damaging effect on 
protein function or splicing” was cited more frequently for reclassified variants in HBRGs 
(10%) (p=0.021).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Frequency of “supporting evidence for benign” used for VUS reclassification in HBRGs and 
MBRGs. N equals the number of variants. Percentages reflect frequency of criteria used for each category of 
genes.  P-values in bold indicate statistical significance. 
‡: No disease association in a small case-control study 
*See Table 2 for a full description of ACMG evidence criteria codes  
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3.3 Triggers that precede VUS reclassification  
The frequencies of each trigger category, or events that triggered the reclassification 
process were calculated for reclassified variants in HBRGs and MBRGs. “Periodic re-review” 
and “New research/data available” were the triggers that were seen most often. 
Reclassified variants in MBRGs (58%) cited “Periodic re-review” significantly more than 
reclassified variants in HBRGs (45%) (p=0.034). Alternatively, “New research/data 
available” was cited significantly more often for reclassified variants in HBRGs (54%) 
versus MBRGs (38%) (p=0.005). “Variant identified in new patient sample” was cited 
significantly more often for reclassified variants in MBRGs (p=0.006).  
 
Figure 8. Frequency of VUS reclassification triggers in HBRGs and MBRGs. N equals the number 
of variants. Percentages reflect frequency of trigger used for each category of genes. P-values in 
bold indicate statistical significance.  
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3.4 Frequency of discrepant classification in public variant database  
 
It was determined that a majority of the reclassified variants in this study (82%, 
506/617) had a discrepant classification in ClinVar, as of February 2019, meaning that at 
least one classification from any other submitter was not equal to the classification given at 
the time of reclassification. The frequencies of discrepant classification between 
reclassified variants in HBRGs and MBRGs were compared, but there was no significant 
difference in the presence or absence of a discrepant classification (p=0.914 and 0.849, 
respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Overall frequency of discrepant variant classification in HBRGs and 
MBRGs. N equals the number of variants. Percentages reflect frequency of discrepant 
variant classification for each category of genes.   
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For reclassified variants with a discrepant classification, the level of discrepancy 
was calculated (Figure 10). A majority of the discrepant classifications seen were 
discrepancy level one (96%), meaning there was one level of classification difference 
between laboratories i.e., VUS vs. likely benign/likely pathogenic. There rest were 
discrepancy level two (4%), meaning there was two levels of classification difference 
between laboratories i.e., VUS vs. benign/pathogenic.  
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Figure 10. Level of discrepancy for 506 (total number) variants with a discrepant variant 
classification as of February 2019. Percentages reflect frequency of different levels of 
discrepant variant classification.  
1: One level of discrepancy (ex. VUS vs. likely benign/likely pathogenic) 
2: Two levels of discrepancy (ex. VUS vs. benign/pathogenic) 
3: Three levels of discrepancy (ex. VLB vs. pathogenic)  
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 The percentage of discrepant variant classifications (based on submissions in 
ClinVar as of February 2019) was also calculated for each year that variants were 
reclassified. The year of variant reclassification with the highest proportion of discrepant 
classifications observed in 2019 was 2014, with 94% (98/104), and the proportion of 
discrepant classifications decreased every year thereafter. The reclassification years that 
had the lowest proportion of discrepant classifications noted in 2019 were 2017 and 2018, 
with 71% in each year (150/211 and 5/7, respectively).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Frequency of discrepant variant classification by year of 
reclassification. Percentages reflect number of discrepant classifications 
(observed in February 2019) out of total variants reclassified in that year. 
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3.5 Average time to VUS reclassification  
The mean time to reclassification differed for variants in HBRGs and MBRGs: 20.9 
months vs. 25.9 months, respectively (p<0.001). The overall median time to reclassification 
was 20.6 months with the median time to reclassification for variants in HBRGs being 18.7 
months and 23.5 months for variants in MBRGs.  
 
The average time to reclassification for variants in each of the 15 genes was also 
calculated and is available in Appendix G. Variants in NF1 and RAD51D had the shortest 
average time to reclassification, while variants in ATM and RAD51C had the longest average 
time to reclassification. 
Figure 12. Average time to VUS reclassification in HBRGs and MBRGs. Blue color indicates 
HBRGs; yellow color represents MBRGs. Box-plot diagram showing the time to VUS 
reclassification in HBRGs and MBRGs. The black center line denotes the median value (50th 
percentile), while the blue and yellow boxes, respectively, contain the 25th to 75th percentiles. 
The black whiskers mark the 5th and 95th percentiles, and values beyond these upper and lower 
bounds are considered outliers, marked with black dots. 
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IV. DISCUSSION 
This study aimed to identify significant trends in VUS reclassification, in particular 
by comparing reclassifications of variants in HBRGs and MBRGs.  The analysis included 
evaluation of reclassification direction (upgrade or downgrade), reclassification criteria, 
triggers that preceded VUS reclassification, and time to reclassification.  Consistent with 
previously published studies, our data showed an overwhelming majority of downgrades in 
617 VUS reclassifications across 15 genes related to breast cancer risk (Mersch et al. 2018, 
Macklin et al. 2017).  However, this study did identify a significant trend in the odds of 
upgrade for reclassified variants in HBRGs over the study period. The most frequently used 
criteria for VUS reclassification in HBRGs were BP6, BS3, BP4_strong, PS2/PM6, and 
updated classification evidence and/or weighting (in support of pathogenicity). 
Alternatively, the most frequently used criteria for VUS reclassification in MBRGs were BS1, 
BP4_strong, and updated classification evidence and/or weighting (in support of benign 
classification). “Periodic re-review” and “variant identified in new patient sample” were the 
two triggers that preceded VUS reclassification for variants in MBRGs most often. “New 
research and/or data available” was the trigger that preceded VUS reclassification in 
HBRGs most often. Additionally, VUSs in HBRGs were reclassified five months sooner, on 
average, than variants in MBRGs.  
 
4.1 VUS reclassification direction over study period   
A notable observation from the analysis concerned the odds of VUS upgrade in 
HBRGs over the study period. The odds of upgrade were 1.68 times higher every year for 
reclassified variants in HBRGs in the study period.  This increase in odds of upgrade is 
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likely due to a number of factors, one being an increase in our variant knowledge base. The 
increase in availability of data, such as de novo events and phenotype, over time seems to 
have led to many of the VUS upgrades in HBRGs observed in this study. This was supported 
by the significant frequency with which VUS reclassification in HBRGs was triggered by 
“new research/data available”. However, it is important to note that the accumulation of 
new data can support both benign and pathogenic directions. Furthermore, guidelines, 
such as those published by ClinGen expert panels in 2018, will help further our 
understanding and application of criteria for variant classification in HBRGs in the future 
(Lee et al. 2018, Mester et al. 2018).  
 
Another factor that influences reclassification is the rapid uptake of multigene panel 
testing in the cancer genetics setting. As the number of individuals being tested increases 
so does the knowledge base for both common and rare variants.  For example, an 
individual’s phenotype and family history are important to consider when weighting 
evidence (PS2/PM6 and PP4). Since it is uncommon for variant classification to be based on 
one individual’s phenotype or family history the more individuals that undergo testing the 
greater the availability of aggregate phenotypic and family history data will be available for 
individual variants. Aggregate data of this nature is more applicable to variants in HBRGs 
due to their higher phenotype penetrance i.e., a greater proportion of individuals carrying a 
pathogenic variant will have breast cancer or a history of breast cancer. Additionally, as the 
number of individuals undergoing testing increases so does our understanding of benign 
genetic variation in MBRGS and HBRGs in the population.  To date, public databases that 
catalog human genetic variation, such as the Genome Aggregation Database (gnomAD), 
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have been overrepresented by genetic data from Caucasian individuals (Hall et al. 2009), 
but as more non-Caucasian individuals undergo genetic testing our understanding of 
genetic variation in those populations will grow.   Furthermore, population-level genetic 
screening for conditions such as hereditary breast and ovarian cancer syndrome, Lynch 
syndrome, and familial hypercholesterolemia may allow for greater understanding of 
benign variation amongst unaffected individuals (Akbari et al. 2017, Gabai-Kapara et al. 
2014).   
 
 VUS upgrades to likely pathogenic or pathogenic are of particular clinical 
importance because of the subsequent medical management changes that accompany these 
upgrades (Daly et al. 2017). In this study, 19% (119/617) of the total reclassified VUSs 
were upgraded to pathogenic or likely pathogenic. This is higher than two previous studies 
on variant reclassification (Mersch et al. 2018, Macklin et al. 2017). In those studies, 8.7% 
(178/2,048) and 3.3% (1/30) of reclassified VUSs were upgraded. These differences 
demonstrate that the rate of VUS upgrade is not only laboratory dependent but potentially 
time dependent. Differences in test volume and ascertainment of tested individuals 
amongst laboratories likely contribute to discrepancies in frequency and direction of VUS 
reclassification. For instance, laboratories with greater volume will aggregate more variant 
and phenotype data which will aid in the classification or reclassification of variants. 
Additionally, the timeframe of this study and previous studies was not exactly the same 
which makes it difficult to make direct comparisons. However, the differences in timeframe 
(with this study extending into 2018) could explain the higher incidence of VUS upgrades 
seen in this study as compared to previous studies. Availability of new research or data in a 
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specific year could have a significant impact on reclassification of previously reported 
variants. For example a large scale clinically validated functional study testing hundreds of 
variants could give strong data towards pathogenicity and therefore lead to reclassification 
of variants.  
 
 The observed differences in VUS reclassification direction across the 15 genes 
highlight potential exceptions to the concept that most VUS reclassifications are 
downgrades. For example, PTEN was shown to have a high proportion of upgrades, 53% 
(8/15). This is consistent with the knowledge that PTEN is a gene with a low rate of benign 
missense variants, and therefore when a missense variant is present it is more likely to be 
pathogenic (Mester et al. 2018). In addition, there are PTEN-specific phenotypic criteria 
and de novo rates which provide substantial weight for criteria in support of pathogenicity.  
Furthermore, because pathogenic variants in PTEN are associated with a heterogeneous 
clinical spectrum an expert panel (EP) was formed to weigh in on PTEN variant 
classification (Mester et al. 2018). Implementation of these refined criteria will likely lead 
to more accurate and timely PTEN variant classification in the future.  
  
 Overall, there are many factors that influence VUS reclassification direction, some of 
which include internal laboratory data, availability of gene-specific criteria, and numbers of 
tested individuals. To further understand VUS reclassifications we looked at the criteria 
that were frequently cited as evidence for reclassification.  
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4.2 Significant differences in criteria used for VUS reclassifications 
  “PS2/PM6 De novo (both maternity and paternity confirmed) in a patient with the 
disease and no family history or assumed de novo, but without confirmation of paternity 
and maternity” was cited exclusively for reclassified variants in HBRGs (13%).  None of the 
reclassified VUSs in MBRGs used PS2/PM6 as the criteria for upgrade. This difference can 
be explained by the inability to use de novo occurrences as criteria for classification for 
variants in MBRGs due to the lack of phenotypic specificity. As a result, parental studies are 
not typically offered as a part of the reclassification process for variants in MBRGs 
therefore that data is not readily available. On the contrary, parental studies for variants in 
HBRGs are routinely performed due to the specific phenotype associated with pathogenic 
variants in these genes. For example, pathogenic variants in TP53 cause Li-Fraumeni 
syndrome which is associated with the development of the following tumors: soft tissue 
sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumors, adrenocortical 
carcinoma, and leukemias. The presence of these tumors in an individual is more 
informative for interpreting de novo data because of their relative scarcity in the general 
population, as compared to breast cancer. In March of 2018, SVI published 
recommendations for the interpretation of de novo criteria (PMS2/PM6) which included a 
point-based system to determine the strength of de novo evidence based upon three 
parameters: confirmed versus assumed de novo status, phenotypic consistency, and 
number of de novo observations (https://clinicalgenome.org/working-groups/sequence-
variant-interpretation/). De novo criteria has since been applied to variant classification in 
MBRGs with the appropriate weighting i.e., PS2_moderate, which may lead to greater 
availability and application of this criteria in the future.  
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Overall, “BP4_strong Amino acid is reference allele in ≥3 primates OR ≥15 mammals” 
was cited 34% (212/617) of the time and showed no bias towards reclassified variants in 
either HBRGs or MBRGs. This criterion was introduced in the Ambry variant classification 
scheme in April of 2015 and accounts for a large proportion of VUS downgrades seen in the 
following years: 2015 (45 of the 107 VUS downgrades), 2016 (95 of the 139 VUS 
downgrades), and 2017 (67 of the 152 downgrades). This suggests that changes to a 
clinical laboratory’s classification scheme can have a significant impact on VUS 
reclassification due to continued refinement of criteria and their weighting.  
 
“BS3 Well-established in vitro or in vivo functional studies show no damaging effect 
on protein function or splicing” was cited significantly more often for reclassified variants 
in HBRGs, specifically BRCA1, BRCA2 and TP53, suggesting a greater availability or 
validation of functional or splicing criteria for these genes. Parsing this data further we see 
that a significant proportion of BS3 criteria were citing splicing variant impact. A splice site 
alteration could potentially affect normal pre-mRNA splicing and be pathogenic via 
disruption of consensus sequences, creation of de novo sequences, or alteration of splicing 
regulatory elements (Spurdle et al. 2008). Traditionally, clinical laboratories have relied on 
published research to provide evidence of splicing variant impact on gene expression or 
protein function. To date, there have been multiple studies to assess the effects of germline 
splicing alterations in breast cancer genes via both in vitro and in vivo studies (Farber-Katz 
et al. 2018, Farrugia et al. 2008, Houdayer et al. 2012, Pesaran et al. 2016, Tesoriero et al. 
2005, Thomassen et al. 2012). More recently, some clinical laboratories have implemented 
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internal research labs to develop and perform assays to evaluate the functional impact of a 
VUS (Pesaran et al. 2016). This integrated approach likely contributed to the frequent use 
of this criterion for VUS reclassification in HBRGs.  Furthermore, large-scale functional 
studies which used massively parallel sequencing to measure the effects of thousands of 
missense variants on PTEN protein intracellular abundance (Matreyek et al. 2018), will 
likely provide additional functional criteria for variant classification or reclassification. 
 
 In addition to advances in laboratory assays, advancements in computational tools 
have led to greater accuracy and efficiency of variant classification (Fortuno et al. 2018, 
Houdayer et al. 2012). In this study, computational data was cited in a number of evidence 
categories: “PP1 Other data supporting pathogenic classification” and 
“BP6/BP4_strong/BS4/BS4_supporting Other data supporting benign classification”. About 
31% (37/119) of VUSs that were reclassified to VLP or pathogenic cited “PM1/5 Mutational 
hotspot, computational data, including structural analysis and/or modeling” as the criteria 
for upgrade. In addition to assessing mutational hotspots, structural biologists assess the 
pathogenicity of variants by analyzing a number of parameters, including but not limited to 
impact on protein stability, impact of the variant on functional domains and protein-
protein interactions. However, these computational tools cannot be applied to all variants 
and all genes and require expertise for appropriate interpretation.  
 
A criterion that was cited exclusively for reclassified variants in HBRGs was “BP6 
Reputable source recently reports variant as benign, but the evidence is not available to the 
laboratory to perform an independent evaluation” (p<0.001). Although this was a line of 
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evidence in the 2015 ACMG-AMP guidelines, in December of 2018 the SVI working group 
appealed to ACMG to remove BP6 from the classification framework (Biesecker et al. 2018). 
The rationale for removal was that alternative criteria should be used instead of BP6 
because it relies on assertions that are not directly linked to the evidence on which it was 
based. The SVI working group further explains that this criterion was appropriate in 2015 
as it was intended to bridge the gap in knowledge amongst clinical laboratories however 
this bridge is no longer needed due to the implementation of resources of public variant 
databases, such as ClinVar. Based on these considerations, laboratories no longer use BP6 
as criteria for variant classification. If this study were to be repeated in the future we would 
likely see a significant decrease or altogether elimination of this criterion as evidence for 
reclassification.  
 
Differences in criteria and weight of criteria used in variant classification exist 
amongst clinical laboratories and likely contribute to observed differences in VUS 
reclassification (Harrison et al. 2017, Harrison et al. 2018, Yang et al. 2017). One study 
analyzed all ClinVar variants classified by two or more submitters and found that 11.7% of 
variants had discrepant interpretations; these were further categorized by level of 
discrepancy and 3.5% of all variants were considered to have medically significant 
discrepancies i.e., pathogenic/VLP versus VUS/benign/VLB (Harrison et al. 2017). Another 
study found that the year of submission to ClinVar played a significant role in discrepancy; 
submissions prior to 2014 were more likely to have discrepant classification due to 
outdated criteria (Yang et al. 2017). These results are generally in agreement with the 
results of our study showing that the percentage of discrepant classifications decreased 
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every year, with the years 2017 and 2018 being the lowest at 71% each (Figure 11, 
150/211 and 5/7 respectively). However, in this study the discrepancy frequencies are 
likely over inflated, as we did not delineate the number of discrepant or concordant 
submissions in Clinvar nor did we differentiate the source of the discrepant classification. 
For example, if there were five submissions in total and one out of the five had a discrepant 
classification this was counted as discrepant. Additionally, there are over 1200 submitters 
in the ClinVar database, of which a handful are considered reputable sources. These factors 
likely explain the high proportion of discrepant classifications seen in this study. A more 
recent study found that out of 49,242 variants, 77.8% had concordant classifications, 
17.9% had VUS to VLB/benign conflicting classifications, 3.1% had pathogenic/VLP versus 
VUS differences and 1.2% had pathogenic/VLP versus benign/VLB difference. This resulted 
in 4.3% of variants having a medically significant difference in classification (Harrison et al. 
2018). It is important to note that the scope and frequency of ClinVar submissions can vary 
significantly by clinical laboratory. In addition prioritizing resubmission of reclassified 
variants and providing an evaluation date  can provide a better representation of a 
laboratory’s current classification (Harrison et al. 2018).  
  
4.3 Significant differences in triggers that precede VUS reclassification 
 “Periodic re-review” was cited significantly more often for reclassified variants in 
MBRGs as compared to HBRGs. The clinical laboratory that provided this dataset re-
reviews variants every six months to assess for updates or availably of new evidence. Data 
from this study suggests that periodic re-review plays an important role in VUS 
reclassification as opposed to other potential triggers. However this could vary between 
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clinical laboratories and not all may have standardized periodic re-review guidelines 
(David et al. 2018). Alternatively, “new research/data available” was cited significantly 
more often for reclassified variants in HBRGs. This difference could be explained by the 
greater availability of new research and data for variants in HBRGs. It is possible that 
researchers are choosing to study HBRGs as opposed to MBRGs, due to the stronger 
association of pathogenic variants identified in an individual and presence of disease 
(genotype-phenotype correlation). Importantly, one reclassification trigger that was 
infrequently cited was “provider requested”. The absence of this trigger is notable given 
that genetic testing laboratories are often inundated with communications from healthcare 
providers to inquire about the status of VUSs. While providers are well within their right to 
re-contact the laboratories, it is worth mentioning that we found no evidence that these 
requests played a significant role in the VUS reclassification process. However, this should 
not discourage patients and providers from re-contacting a laboratory about the status of a 
particular variant, especially in the context of pursing additional genetic studies or updates 
to family history or clinical information.  
 
4.4 Differences in time to VUS reclassification  
 The median time to VUS reclassification was significantly shorter for variants in 
HBRGs than MBRGs. This difference may be explained by factors previously outlined above 
such as “new research/data available” due to new internal variant data and 
implementation of protein functional assays. Overall, the median time to reclassification 
was 20.6 months. This is lower than previously published studies, which showed medians 
of 39 and 30.6 months (Garcia et al. 2014, Mersch et al. 2018). The median time to VUS 
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reclassification in HBRGs in our data was 18.7 months and the difference in median time to 
VUS reclassification between HBRGs and MBRGs was 4.8 months. This difference could 
impact the timeframe of variant classification inquiry by health-care providers as well as 
the timeframe of patient follow-up. Reclassification from VUS to VLB/benign in a timely 
manner may help minimize the risk of inappropriate management and unnecessary 
anxiety. Traditionally, patients are told to return to clinic for updates anywhere from 1 to 3 
years following the results of their genetic testing, should a VUS be identified (Murray et al. 
2011). Given the VUS reclassification times shown in this study, healthcare providers 
should consider revising their recommendation based on the category of gene (HBRG or 
MBRG) the VUS is identified in.  
 
4.5 Events following VUS reclassification 
 While laboratories make every effort to resolve VUS classification, it can be 
challenging for laboratories to provide efficient and effective communication of variant 
reclassification when it occurs. There is currently no clear legal duty on either the 
laboratory or healthcare provider to re-contact patients regarding variant reclassification. 
Although there are no clear legal guidelines on the duty to re-contact patients following 
variant reclassification, ACMG has published a position statement which includes legal, 
ethical and practical issues that should be considered (David et al. 2018). Ultimately, the 
issue of re-contact comes down to the principle of beneficence, defined as “the promotion 
of well-being in others i.e., to do good or prevent harm” (Uhlmann et al. 2011). This ethical 
principle applies to the duty to re-contact particularly in circumstances that may affect 
medical management. There are several practical issues which impede re-contacting 
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patients including: relocation of patients, providers or healthcare networks and difficulty 
navigating electronic health records. While recognizing that variant reclassification is 
inevitable, ACMG acknowledges that the responsibility of re-contact is shared among the 
ordering healthcare provider, the clinical testing laboratory, and the patient. However, it is 
important to note that clinical testing laboratories do not have direct contact with patients 
regarding their test results or reclassification of results. Therefore, it is important for the 
ordering healthcare provider to inform the patient that there is a possibility of variant 
reclassification, particularly in the setting of a VUS result, and that up-to-date contact 
information should be provided. Similarly, healthcare providers need to make every effort 
to provide clinical laboratories with the most effective way of communicating and 
recontacting the provider (fax, email, provider portal, etc.), considering that the 
responsibility of informing the ordering provider of variant reclassification rests solely 
with the clinical laboratory (David et al. 2018).  
 
4.6 Limitations  
The first limitation of this study is that it only included VUS reclassifications and did 
not ascertain VUSs whose classification did not change over the study period. Due to this, 
an overall VUS reclassification rate was not described for this data set, and an overall 
reclassification rate is useful to both patients and providers.  
 
A second limitation of this study is that variant data was collected from a single 
commercial laboratory. In addition to collecting from a single commercial laboratory the 
data was collected by a single individual. However, the error rate, which was estimated as 
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1.45%, is low enough that it is unlikely to affect any of the major conclusions of this study. 
While many laboratories follow the ACMG-AMP variant classification criteria, (Richards et 
al. 2015) each clinical laboratory has their own specified policies and practices and 
therefore the results of this study are limited by those for this individual laboratory.  
 
A third limitation is that several of the genes such as PTEN, BARD1, CHEK2, RAD50, 
RAD51C, and RAD51D, had less than 20 variants included in this study. An analysis 
including low variant counts will be underpowered with respect to detecting a difference.  
 
A fourth limitation of this study involves the collection of discrepant classification in 
ClinVar. As previously stated, the presence of at least one discrepant classification from 
another laboratory was counted as discrepant, regardless of the number of other 
concordant classifications. In future analyses, discrepant classification would be more 
accurately represented by collecting the number and source of discrepant and concordant 
classifications in ClinVar. Additionally, quantifying the presence of medically significant 
discrepancies ex., VUS versus VLP or pathogenic, would help provide representation of 
differences that impact medical management.  
 
A final limitation of this study involves the logistic regression analysis. The analysis 
assumes that the opportunity for variant reclassification is the same across the study 
period. However, as previously mentioned the clinical laboratory that provided this data 
set incorporated numerous updates to their classification scheme including “new 
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classification evidence and/or weighting of evidence” during the study period. These 
updates were not accounted for in the logistic regression model.   
 
4.7 Future Directions  
 An important next step in continuing similar research would be to ascertain the 
overall VUS reclassification rate, direction, evidence used for reclassification, and 
reclassification triggers from several commercial laboratories. An analysis that includes 
variant information from multiple commercial laboratories would help substantiate the 
results seen in this study or highlight differences between laboratories. Additionally, 
collecting this data over a longer time period might help reveal trends that were not seen in 
this study. Finally, an analysis of evidence used across multiple laboratories might help 
elucidate gaps or misinformation in variant classification.  
 
This study did not document the clinical phenotypes associated with the patients 
and families carrying each variant, which would have made for an interesting analysis. An 
analysis of this nature could include demographic, phenotypic and family history 
information for each patient and variant which would allow for further analysis including 
aggregate phenotypic data and likelihood of VUS upgrade.  This study was able to 
tangentially analyze this by quantifying “PP4 Patient’s phenotype or family history is highly 
specific for a disease with a single genetic etiology” and “PP1_strong/PP1_moderate 
cosegregation with disease in multiple affected family members in a gene definitively 
known to cause the disease”. However, a likelihood of upgrade for each variant was not 
quantified in this study. Additionally, sharing one of the overall conclusions of this study, 
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that most reclassified VUSs were downgraded, with patients and healthcare providers may 
reduce their VUS-related anxiety. Surveying or interviewing patients or healthcare 
providers and their attitudes toward this information could glean useful insight into VUS-
related anxiety. For instance, patients who are presented with the information that a 
majority of reclassified VUSs are downgraded may have a significant reduction in their 
VUS-related anxiety.  
 
4.8 Conclusions  
 The results of this study support previously published data showing an overall trend 
toward VUS downgrades when combining HBRGs and MBRGs (Mersch et al. 2018, Macklin 
et al. 2017). However, when looking at variants that were reclassified in HBRGs the odds of 
upgrade increased in each subsequent year. The odds of upgrade were 1.68 higher every 
year for variants in HBRGS in the study period.  The differences in criteria used for 
reclassification between reclassified variants in HBRGs and MBRGs highlight the 
complexity of variant classification. Additionally, the difference in triggers that precede 
VUS reclassification sheds new light on the process of reclassification initiation and what 
role health care providers and patients might play in this process, and the timing of that 
intervention. 
 
The primary purpose of clinical laboratory testing in hereditary breast cancer 
predisposition is to support medical management of cancer risk. In the clinic, genetic 
testing is generally used to identify or confirm the cause of apparently hereditary disease. 
Given the complexity of genetic testing, the best outcomes result from health-care 
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providers and clinical laboratories working collaboratively. An important aspect of variant 
classification that was not addressed in this study is detailed clinical information such as 
patient and family history, physical exam findings, and previous laboratory testing. For 
instance, further clarification with the health-care provider and patient may uncover 
additional evidence to support a variant classification. It is important to note that variant 
analysis and interpretation is based on the available information at that time and can 
evolve over time as new data become available. A Bayesian framework of the ACMG-AMP 
guidelines is available which provides mathematical probabilities of pathogenicity for each 
classification category (Tavtigian et al. 2018). The results of the Tavtigian et al. study  
provide a quantitative framework for the ACMG-AMP guidelines, allowing for further 
refinement of the evidence categories and combination rules.  The results of our study 
provide a better understanding of the VUS reclassification process and facilitate effective 
VUS reclassification counseling and education.  
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APPENDIX A 
 
Evidence Category  Criteria  
Very strong for 
pathogenicity  
PVS1 null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or 
multiexon deletion) in a gene where LOF is a known mechanism of disease 
Caveats:     
 Beware of genes where LOF is not a known disease mechanism (e.g., GFAP, MYH7)  
 Use caution interpreting LOF variants at the extreme 3′ end of a gene  
 Use caution with splice variants that are predicted to lead to exon skipping but leave the 
remainder of the protein intact  
 Use caution in the presence of multiple transcripts 
Strong for 
pathogenicity  
PS1 Same amino acid change as a previously established pathogenic variant regardless of nucleotide 
change  
 Example: Val→Leu caused by either G>C or G>T in the same codon  
 Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level 
PS2 De novo (both maternity and paternity confirmed) in a patient with the disease and no family 
history  
 Note: Confirmation of paternity only is insufficient. Egg donation, surrogate motherhood, 
errors in embryo transfer, and so on, can contribute to nonmaternity. 
PS3 Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene 
or gene product  
 Note: Functional studies that have been validated and shown to be reproducible and robust in 
a clinical diagnostic laboratory setting are considered the most well established. 
PS4 The prevalence of the variant in affected individuals is significantly increased compared with the 
prevalence in controls  
 Note 1: Relative risk or OR, as obtained from case–control studies, is >5.0, and the 
confidence interval around the estimate of relative risk or OR does not include 1.0. See the 
article for detailed guidance.  
 Note 2: In instances of very rare variants where case–control studies may not reach statistical 
significance, the prior observation of the variant in multiple unrelated patients with the same 
phenotype, and its absence in controls, may be used as moderate level of evidence. 
Moderate for 
pathogenicity 
PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., 
active site of an enzyme) without benign variation 
PM2 Absent from controls (or at extremely low frequency if recessive) (Table 6) in Exome 
Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium  
 Caveat: Population data for insertions/deletions may be poorly called by next-generation 
sequencing. 
PM3 For recessive disorders, detected in trans with a pathogenic variant  
 Note: This requires testing of parents (or offspring) to determine phase. 
PM4 Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-
loss variants 
PM5 Novel missense change at an amino acid residue where a different missense change determined to 
be pathogenic has been seen before  
 Example: Arg156His is pathogenic; now you observe Arg156Cys  
 Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level. 
PM6 Assumed de novo, but without confirmation of paternity and maternity 
Supporting for 
pathogenicity 
PP1 Cosegregation with disease in multiple affected family members in a gene definitively known to 
cause the disease  
 Note: May be used as stronger evidence with increasing segregation data 
PP2 Missense variant in a gene that has a low rate of benign missense variation and in which missense 
variants are a common mechanism of disease 
PP3 Multiple lines of computational evidence support a deleterious effect on the gene or gene product 
(conservation, evolutionary, splicing impact, etc.)  
 Caveat: Because many in silico algorithms use the same or very similar input for their 
predictions, each algorithm should not be counted as an independent criterion. PP3 can be 
used only once in any evaluation of a variant. 
PP4 Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology 
PP5 Reputable source recently reports variant as pathogenic, but the evidence is not available to the 
laboratory to perform an independent evaluation 
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Stand-alone for 
benign  
BA1 Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome 
Aggregation Consortium 
Strong for benign  BS1 Allele frequency is greater than expected for disorder (see Table 6) 
BS2 Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or 
X-linked (hemizygous) disorder, with full penetrance expected at an early age 
BS3 Well-established in vitro or in vivo functional studies show no damaging effect on protein 
function or splicing 
BS4 Lack of segregation in affected members of a family  
 Caveat: The presence of phenocopies for common phenotypes (i.e., cancer, epilepsy) can 
mimic lack of segregation among affected individuals. Also, families may have more than 
one pathogenic variant contributing to an autosomal dominant disorder, further confounding 
an apparent lack of segregation. 
Supporting for 
benign  
BP1 Missense variant in a gene for which primarily truncating variants are known to cause disease 
BP2 Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or 
observed in cis with a pathogenic variant in any inheritance pattern 
BP3 In-frame deletions/insertions in a repetitive region without a known function 
BP4 Multiple lines of computational evidence suggest no impact on gene or gene product 
(conservation, evolutionary, splicing impact, etc.)  
 Caveat: Because many in silico algorithms use the same or very similar input for their 
predictions, each algorithm cannot be counted as an independent criterion. BP4 can be used 
only once in any evaluation of a variant. 
BP5 Variant found in a case with an alternate molecular basis for disease 
BP6 Reputable source recently reports variant as benign, but the evidence is not available to the 
laboratory to perform an independent evaluation 
BP7 A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the 
splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly 
conserved 
*Adapted from Richards et al. 2015 
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APPENDIX B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This scheme is available at 
https://www.ambrygen.com/file/material/view/272/Variant_ClassificationScheme_0617_Final.pdf 
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APPENDIX C 
  
OFFICE OF RESEARCH 
INSTITUTIONAL REVIEW BOARD 
PAGE 1 OF 2 
December 17, 2017 
KIRSTEN ANNE KELLY 
PEDIATRICS 
 
HS# 2018-4835:      Investigating Variants of Uncertain Significance Reclassification Drivers 
in Breast Cancer Genes [Application for IRB Review (APP) # 13125]    
Dear Kirsten Kelly, 
A sub-committee of Institutional Review Board (IRB) reviewed the above-referenced item 
at its meeting on December 13, 2018 and concluded that the project, as described, may not 
qualify as human subjects research, however, further clarification is required from the 
team. 
The following guidelines help determine whether the study constitutes human subjects 
research: 
Research - a systematic investigation, including research development, testing and 
evaluation, designed to develop or contribute to generalizable knowledge. 
A systematic approach involves a predetermined system, method or a plan for studying a 
specific topic, answering a specific question, testing a specific hypothesis, or developing 
theory. A systematic approach includes the collection of information and/or biospecimens, 
and analysis either quantitative or qualitative. 
Activities designed to develop or contribute to generalizable knowledge are those 
activities designed to draw general conclusions, inform policy, or generalize outcomes 
beyond the specific group, entity, or institution (i.e., to elaborate, to be an important factor 
in identifying or expanding truths, facts, information that are universally applicable). 
Human subject - a living individual about whom an investigator (whether faculty, student, 
or staff) conducting research obtains: (1) data through intervention or interaction with 
the individual; or (2) identifiable private information. 
Intervention includes both physical procedures by which information is gathered (for 
example, venipuncture) and manipulations of the subject or the subject's environment that 
are performed for research purposes.  
Interaction includes communication or interpersonal contact between investigator and 
subject. 
Please note that for the proposed activities to be considered Human Subjects Research, it 
needs to meet the criteria for both Research and Human Subjects. In this case, the project 
does not meet the criteria for Human Subjects as the information abstracted appears to be 
de-identifiable. 
The Committee required the following clarifications: 
·Although UCI members are part-time employees at Ambry Genetics, it may be that the 
study could be considered Non-Human Subjects Research. Please confirm that UCI 
part-time employees at Ambry Genetics would not seek to re-identify subjects when 
abstracting data. 
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As such, the project would not meet the definition of human subjects/research and UCI IRB 
approval is not required to pursue your activities. Instead, you will receive an official 
Confirmation of Non-Human Subjects Research stating that UC Irvine does not require that 
you receive IRB Approval. 
Please indicate whether you agree with this assessment. 
 Otherwise, if UCI IRB Approval is crucial, please address the following: 
  
o After reading the procedures for this project, it appears that all research 
procedures will be conducted at Ambry Genetics. As such, 
please clarify UCI’s intellectual contribution to the project. 
  
o Please further clarify how this study is human subjects research. 
  
o In addition, please clarify the HIPAA procedures at Ambry Genetics. As the 
data collected will be done at a non-UCI site, UCI may be unable to offer a 
Total Waiver of HIPAA Authorization.  
  
Note: After a response is received, the responses will be re-assessed and the study team will 
receive additional comments and revisions needed to the submitted documents. 
If you have any questions regarding the IRB’s review, please respond to this e-mail, or call 
the Office of Research at 949-824-5047.  
 
RE:      Activities that Do Not Constitute Human Subjects Research 
The University of California, Irvine (UCI) Human Research Protections Program complies 
with all review requirements defined in 45 CFR Part 46, Protection of Human Subjects. 45 
CFR 46.102(e) defines research as “a systematic investigation, including research 
development, testing and evaluation, designed to develop or contribute to generalizable 
knowledge; and 45 CFR 46.102(f) defines a human subject as “a living individual about 
whom an investigator conducting research obtains 1) data through intervention or 
interaction with the individual; or 2) identifiable private information.” Private information 
must be individually identifiable (i.e., the identity of the subject is or may readily be 
ascertained by the investigator or associated with the information) to meet the definition 
of human subject.  
  
The UCI Human Research Protections (HRP) staff reviewed the information you submitted 
pertaining to your project “Investigating Variants of Uncertain Significance Reclassification 
Drivers in Breast Cancer Genes” and concluded that the project, as described, does not 
qualify as human subjects research because the activities do not involve human subjects. 
The team will not seek to re-identify subjects when abstracting data from Ambry Genetics. 
Therefore, the activities are not subject to UCI IRB review and approval.  If your project 
changes in ways that may affect this determination, please contact the HRP staff for 
additional guidance. 
  
Beverley Alberola, CIP 
IRB Alternate Member 
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APPENDIX D 
 
Criteria Cited 
Other moderate data supporting pathogenic classification 
PM1/5 Mutational hotspot, computational data, including structural analysis 
and/or modeling 
Updated classification evidence and/or weighting 
Other data supporting pathogenic classification 
PM1_supporting Computational data, including structural analysis and/or modeling 
Other strong data supporting benign classification 
BP4_strong Amino acid is reference allele in ≥3 primates OR ≥15 mammals  
BS1 Internal allele frequency greater than expected  based on disease prevalence 
Updated classification evidence and/or weighting 
Other data supporting benign classification 
BP6 Reputable source recently reports variant as benign, but the evidence is not 
available to the laboratory to perform an 
independent evaluation 
BP4_strong Amino acid is reference allele in ≥3 primates OR ≥15 mammals 
BP4 Computational data, including structural analysis and/or modeling 
BS4_supporting Cosegregation and family history data*  
*International Agency for Research on Cancer (IARC) and Open Variation 
Database (LOVD) (https://www.lovd.nl/) 
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APPENDIX E 
 
 
 
 
Categories of Triggers that Precede 
Reclassification 
Variant identified in new patient sample  
Periodic re-review  
New research/data available  
Provider requested   
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APPENDIX F 
 
RStudio logistic regression model code  
 
#read in data and remove 2018 
ds = read.csv("C:/Users/lishiz/Desktop/Book1.csv") 
ds = ds[which(ds$Year != 2018), ] 
 
#Create a new outcome named as outcome2. Upgrade is coded as 1 in outcome2. 
ds$outcome2 = (ds$Outcome != "Upgrade") 
 
#fit a logistic regression in each high and moderate penetrance group. 
 
#high penetrance group 
ds_high = ds[which(ds$Group == "High "),] 
model1 = glm(outcome2 ~ Year, data = ds_high, family = "binomial") 
 
summary(model1) 
table(ds_high$Outcome, ds_high$Year) 
#results 
or = exp(summary(model1)$coefficients[2, 1]) 
lower = exp(summary(model1)$coefficients[2, 1]-1.96*summary(model1)$coefficients[2, 2]) 
higher = exp(summary(model1)$coefficients[2, 1]+1.96*summary(model1)$coefficients[2, 2]) 
print(c(or, lower, higher))   ##odds ratio and 95% confidence interval 
  
#moderate penetrance group 
ds_moderate = ds[which(ds$Group == "Moderate "),] 
model2 = glm(outcome2 ~ Year, data = ds_moderate, family = "binomial") 
 
summary(model2) 
table(ds_moderate$Outcome, ds_moderate$Year) 
#results 
or = exp(summary(model2)$coefficients[2, 1]) 
lower = exp(summary(model2)$coefficients[2, 1]-1.96*summary(model2)$coefficients[2, 2]) 
higher = exp(summary(model2)$coefficients[2, 1]+1.96*summary(model2)$coefficients[2, 2]) 
print(c(or, lower, higher))   ##odds ratio and 95% confidence interval 
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